Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Monday, 13 August 2007

While You Were at the Beer Festival

Posted on 04:00 by Unknown
A friend of IN VIVO Blog reads his GBBF-approved magazine

Massive beer festivals and keeping up with the weekend's news don't necessarily mix, but damnit we'll do our best.
  • Glass half-full ... The Boston Globe is reporting this morning that FoldRx, a biotech specializing in molecular chaperones that can return misfolded proteins to their correct shapes, will receive a serious chunk of change from the Cystic Fibrosis Foundation. The $22 million grant will be paid out over five years, says the Globe (Our most recent feature on venture philanthropy can be found here.)
  • Glass half-empty ... Cost cutting: not just for Big Pharma. Amgen isn't saying what the cuts will look like, but the big biotech said in a regulatory filing on Friday that hits to its ESA franchise will result in a fresh look at its cost structure.
  • Through the Looking Glass ... we've ignored this blog-friendly story so far if only because we don't have much to add beyond "eeesh." But for a roundup of the Johnson & Johnson-sues-the-Red Cross kerfuffle, and the various guffaws and high-horsing around the web, see the never-subtle Pharma Marketing Blog.
  • What's in your glass? Finally, some tasting notes from the Great British Beer Festival for any ale aficionados out there ...

As you can see from the picture above we spent some time camped out in front of the Caledonian and Sharps booths, mostly because these breweries rarely disappoint. The XPA and Deuchars IPA were outstanding as usual, and the mysterious Rebus 20 was also quite good. Sharps' Atlantic IPA was delicious and we also liked their Cornish Coaster. No surprises there.

What did surprise us a bit were the higher-than-the-pub prices for some beers at the festival (3 quid per pint was not uncommon), and the fact that we 'discovered' only a few new ales that were top-notch. (That said, we couldn't try all 450. Maybe next year.)

Can't wait to try again: Jennings Cocker Hoop from Marston's and Caledonian's XPA.

Give it a miss: A Fist Full of Hops from Falstaff and Bullmastiff South's Welsh Gold.

If you were at the festival or just have a favorite ale to tell us about, lets hear it in the comments...

Email ThisBlogThis!Share to XShare to Facebook
Posted in mmm beer, While You Were ... | No comments
Newer Post Older Post Home
View mobile version

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Take the Money…or Let it Roll?
    In his talk introducing the top-10 most licensable oncology drugs at the Therapeutic Alliances conference last Friday, Ben Bonifant of Campb...
  • $80 million upfront? About Average
    So Synta’s PR firm were pushing today’s deal with GlaxoSmithKline at us as “one of the biggest product deals this year” and indeed “among t...
  • Beijing Boost for Japanese Encephalitis Vaccine
    China has been preparing feverishly for the Beijing Olympics for years to showcase its new world position and economic power. China's co...
  • Reporting on Exubera: an A-Buse
    Many analysts have questioned the potential of Pfizer’s inhaled insulin, Exubera . Nonetheless, it was more than surprising to see the comme...
  • The Best Defense Is a Good Offense, Or Something Like That
    Merck and Schering-Plough put out a release a few minutes ago responding to critics of ENHANCE and the trial results' fallout: WHITEHOU...
  • Public Confidence in Drug Safety: Solution is in "Plane" Sight
    Active surveillance and data mining are scary, right? It is common wisdom that these tools in the hands of academics, health plans and regul...
  • Addex Ups Dealmaking Ante
    Addex Pharma today took a step up the dealmaking ladder , partnering its pre-IND positive allosteric modulator ADX63365 and back-up compound...
  • Pfizer UK Gets “Closer to Customers”
    “Increased patient safety” drove Pfizer’s recent deal with UK wholesaler Alliance UniChem, according to the partners. But no one’s buying th...
  • Another Look at Asia
    As a small follow up to our post last week on Sofinnova Partners' hiring an Asia-focused professional, VentureWire Lifescience reported...
  • Deals of the Week: "King of Pain" Edition
    Admittedly, it's been a quiet week for biz dev in pharma land. The big news has been clinical. On the positive side, the diabetes triumv...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ▼  August (29)
      • Generic EPO Should be a Big Deal. But Is It?
      • Is it Getting Breezy in Here?
      • Bayer-Schering Biz Dev: Reorganized and Ready to Deal
      • The One-Two Punch in Venture Capital
      • While You Were Redesigning Your Blog
      • No Wait! Make it a Venti!
      • Ready, set....
      • Take The Money and Run
      • Old Medicine in New Bottles
      • CardioNet's Not So Big Surprise
      • While You Were Watching the Weather Channel
      • Seeing Double: Ophthotech's $36mm Series A
      • Avandia and Rezulin Redux
      • They MIGHT Be Giants
      • Wyeth's Leaky Pipeline
      • Northwest Under the Hammer
      • The Most Important Deal of the Last 12 Months
      • While You Were at the Beer Festival
      • Are These Large-Molecule Twins Identical? The Bios...
      • The Return of Lord Kesslermort
      • Another Co-Promote Bites the Dust
      • FDA and Drug Safety: It Keeps Getting Worse
      • Insight + Preparation + Dumb Luck = Blockbuster
      • Medtronic/Kyphon: Averting a Shake-Up in Spine...F...
      • Drug Safety...or Food Safety...or Tobacco Safety.....
      • While You Were Making History*
      • Once in a Blue Moon: SGP's Stock Offering
      • Novartis: Having & Eating Its Cake
      • Is Partial Agonism the Key to PPAR Success?
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile